Literature DB >> 16028105

Study on brain targeting of raltitrexed following intranasal administration in rats.

Dongxing Wang1, Yongliang Gao, Liuhong Yun.   

Abstract

PURPOSE: To investigate the levels of raltitrexed (RTX) in blood and different brain tissues in rats and to find out whether there is any direct drug transport from nasal cavity to brain tissues following intranasal (i.n.) administration.
METHODS: Raltitrexed was administered to male Sprague-Dawley rats either intranasally or intravenously. Drug concentrations in blood and brain tissues were determined at different times post dosing.
RESULTS: The plasma levels achieved after i.n. administration were significantly lower than those following intravenous (i.v.) administration (P < 0.05) before 120 min; but were significantly higher (P < 0.05) after 120 min. Following i.n. administration, RTX concentrations in different brain tissues were constantly detected for quite a long time and differed significantly from each other, the rank order being C (OB) > C (OT) > C (CR) > C (CL). On the contrary, RTX appeared only at the initial two or three time points in different brain regions after i.v. injection, and the concentrations were similar. AUC values in four brain regions by the nasal route were 54- to 121-fold compared with the i.v. route, the drug targeting index (DTI) values of nasal route were 71-158 for different brain regions, and about 99% of RTX content within 360 min in the brain were transported via the olfactory pathway.
CONCLUSIONS: These results showed that antineoplastic RTX could be directly transported into the brain via the olfactory pathway in rats.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16028105     DOI: 10.1007/s00280-005-0018-3

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  16 in total

1.  New therapeutic approaches for brainstem tumors: a comparison of delivery routes using nanoliposomal irinotecan in an animal model.

Authors:  Nundia Louis; Sharon Liu; Xingyao He; Daryl C Drummond; Charles O Noble; Stewart Goldman; Sabine Mueller; Krystof Bankiewicz; Nalin Gupta; Rintaro Hashizume
Journal:  J Neurooncol       Date:  2017-11-23       Impact factor: 4.130

Review 2.  A systematic review of inhaled intranasal therapy for central nervous system neoplasms: an emerging therapeutic option.

Authors:  Asa Peterson; Amy Bansal; Florence Hofman; Thomas C Chen; Gabriel Zada
Journal:  J Neurooncol       Date:  2014-01-08       Impact factor: 4.130

3.  Intranasal salvinorin A improves neurological outcome in rhesus monkey ischemic stroke model using autologous blood clot.

Authors:  Longfei Wu; Di Wu; Jian Chen; Chunhua Chen; Tianqi Yao; Xiaoduo He; Yanqin Ma; Xinglong Zhi; Renyu Liu; Xunming Ji
Journal:  J Cereb Blood Flow Metab       Date:  2020-07-02       Impact factor: 6.200

Review 4.  Challenges and opportunities to penetrate the blood-brain barrier for brain cancer therapy.

Authors:  Dannielle H Upton; Caitlin Ung; Sandra M George; Maria Tsoli; Maria Kavallaris; David S Ziegler
Journal:  Theranostics       Date:  2022-06-06       Impact factor: 11.600

5.  New therapeutic approach for brain tumors: Intranasal delivery of telomerase inhibitor GRN163.

Authors:  Rintaro Hashizume; Tomoko Ozawa; Sergei M Gryaznov; Andrew W Bollen; Kathleen R Lamborn; William H Frey; Dennis F Deen
Journal:  Neuro Oncol       Date:  2008-02-20       Impact factor: 12.300

Review 6.  Strategies for intranasal delivery of therapeutics for the prevention and treatment of neuroAIDS.

Authors:  Leah R Hanson; William H Frey
Journal:  J Neuroimmune Pharmacol       Date:  2006-09-15       Impact factor: 4.147

Review 7.  Blood brain barrier: a challenge for effectual therapy of brain tumors.

Authors:  Arijit Bhowmik; Rajni Khan; Mrinal Kanti Ghosh
Journal:  Biomed Res Int       Date:  2015-03-19       Impact factor: 3.411

Review 8.  Immune Suppression during Oncolytic Virotherapy for High-Grade Glioma; Yes or No?

Authors:  Carolien A E Koks; Steven De Vleeschouwer; Norbert Graf; Stefaan W Van Gool
Journal:  J Cancer       Date:  2015-01-15       Impact factor: 4.207

Review 9.  Intranasal administration of acetylcholinesterase inhibitors.

Authors:  Henry R Costantino; Alexis Kays Leonard; Gordon Brandt; Paul H Johnson; Steven C Quay
Journal:  BMC Neurosci       Date:  2008-12-10       Impact factor: 3.288

Review 10.  Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease.

Authors:  Leah R Hanson; William H Frey
Journal:  BMC Neurosci       Date:  2008-12-10       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.